TNF and inflammatory bowel disease: ,2 The therapeutic armamentarium for IBD has rapidly expanded in the past decade, and now includes therapies targeting inflammatory cytokines (eg, tumor necrosis factor-α [anti-TNFα], interleukin-12 [IL12] and/or IL23), leukocyte migration (via integrin-α4β7 or the sphingosine-1-phosphate receptor), and kinase signaling (ie, the Janus kinase [JAK] family).3